About CarePluss

CarePluss Pharma, was established in 2004 in Baja, California, Mexico to create and provide treatment products that address the requests and needs of physicians and their patients. CarePluss is a specialty pharmaceutical company that listens and cares!

CarePluss has identified an extraordinary opportunity to develop and commercialize genuinely innovative products in the fields of dermatological skin care, fat loss, and anti-aging solutions. CarePluss is poised to capitalize upon the significant void that exists in the marketplace by introducing its innovative and proprietary portfolio of products that treat skin conditions, fat loss, and those conditions previously treated only by plastic surgery. CarePluss, using its two-pronged approach, is positioning itself to become a leading provider of original treatment products principally in Mexico, Europe, the USA and Canada. CarePluss will also expand into other international markets through the development of distribution agreements and strategic partnerships.

Innovation is the key! Improving skin appearance, skin health and providing a non-surgical answer to a youthful appearance assures CarePluss of growth and profitability.

CarePluss values its diversity as a source of strength. Their current portfolio of completed original treatment products address the significant, under-filled needs of the melasma /hyperpigmentation, under-eye dark circles, area fat loss/cellulite, and acne markets.

Sales of pharmaceutical products reported by IMS in the developed countries of the world for 12 months ending September 2006 was $380 billion US, having grown by 5% during the year. Sales of dermatological type products in the same countries during the same time was $10.4 billion US. As importantly, the combination of these specific therapy areas account for a large percentage of the overall value of the dermatology, skin treatment and fat loss market, thereby demonstrating the Company's strategic commitment to the skin treatment and anti-aging fields.

CarePluss Pharma will leverage its innovative treatment products to capitalize on these underserved specific target markets, thus largely avoiding direct competition from major multinational competitors and boutique specialty companies.